Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
To assess the tolerability and safety of hOKT3g1 (Ala-Ala) after a 12-day dosing regimen
administered via intravenous infusion. To assess the pharmacokinetics of hOKT3g1 (Ala-Ala).
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)